Clinical utility of prostate-specific antigen mass ratio for prediction of prostate cancer detection on a repeated prostate biopsy

Won Ki Lee, Sang Chul Lee, Sung Kyu Hong, Sang Eun Lee, Won Suk Choi, Seok-Soo Byun

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: To assess the clinical utility of the prostate-specific antigen mass ratio (PSA-MR), a newly developed PSA derivative, simply defined as the (i) PSA density (PSA-D) multiplied by the plasma volume or (ii) total PSA amount in circulation per prostate volume, for predicting prostate cancer (PCa) among men undergoing repeated prostate biopsy (PBx). Materials and Methods: Patients (n = 286), who underwent a repeated PBx, were analyzed. The various parameters associated with PCa detection were noted in each patient. PSA-MR was also calculated. Results: PCa was detected in 63 (22.0%) of 286 patients. PSA-MR was the independent predictor in the univariate- and multivariate logistic regression analyses (OR = 3.448, p = 0.001 and OR = 13.430, p = 0.033, respectively). A nomogram that incorporated PSA-MR was considered a useful tool (predictive accuracy: 79.2%, 95% CI: 0.726-0.858, p < 0.001). Furthermore, a nomogram that incorporated PSA-MR would have avoided 59.6% of unnecessary repeated PBx. The predictive accuracy of PSA-MR was also superior to that of PSA or PSA-D (p = 0.013 and 0.009, respectively). Conclusions: PSA-MR was an independent predictor, and its consideration would have avoided 59.6% of unnecessary repeated PBx for PCa detection. PSA-MR was also superior than PSA or PSA-D. Our results support the use of PSA-MR to facilitate counseling with patients after a negative initial PBx, and use of PSA-MR might reduce further unnecessary biopsies.

Original languageEnglish
Pages (from-to)493-498
Number of pages6
JournalInternational Braz J Urol
Volume40
Issue number4
DOIs
StatePublished - 1 Jan 2014

Fingerprint

Prostate-Specific Antigen
Prostate
Prostatic Neoplasms
Biopsy
Nomograms
Plasma Volume
Counseling
Logistic Models
Regression Analysis

Keywords

  • Biopsy
  • Mass Screening
  • Prostate-Specific Antigen
  • Prostatic Neoplasms

Cite this

@article{749301ba8c5c4dcdbc2a212668ceb973,
title = "Clinical utility of prostate-specific antigen mass ratio for prediction of prostate cancer detection on a repeated prostate biopsy",
abstract = "Purpose: To assess the clinical utility of the prostate-specific antigen mass ratio (PSA-MR), a newly developed PSA derivative, simply defined as the (i) PSA density (PSA-D) multiplied by the plasma volume or (ii) total PSA amount in circulation per prostate volume, for predicting prostate cancer (PCa) among men undergoing repeated prostate biopsy (PBx). Materials and Methods: Patients (n = 286), who underwent a repeated PBx, were analyzed. The various parameters associated with PCa detection were noted in each patient. PSA-MR was also calculated. Results: PCa was detected in 63 (22.0{\%}) of 286 patients. PSA-MR was the independent predictor in the univariate- and multivariate logistic regression analyses (OR = 3.448, p = 0.001 and OR = 13.430, p = 0.033, respectively). A nomogram that incorporated PSA-MR was considered a useful tool (predictive accuracy: 79.2{\%}, 95{\%} CI: 0.726-0.858, p < 0.001). Furthermore, a nomogram that incorporated PSA-MR would have avoided 59.6{\%} of unnecessary repeated PBx. The predictive accuracy of PSA-MR was also superior to that of PSA or PSA-D (p = 0.013 and 0.009, respectively). Conclusions: PSA-MR was an independent predictor, and its consideration would have avoided 59.6{\%} of unnecessary repeated PBx for PCa detection. PSA-MR was also superior than PSA or PSA-D. Our results support the use of PSA-MR to facilitate counseling with patients after a negative initial PBx, and use of PSA-MR might reduce further unnecessary biopsies.",
keywords = "Biopsy, Mass Screening, Prostate-Specific Antigen, Prostatic Neoplasms",
author = "Lee, {Won Ki} and Lee, {Sang Chul} and Hong, {Sung Kyu} and Lee, {Sang Eun} and Choi, {Won Suk} and Seok-Soo Byun",
year = "2014",
month = "1",
day = "1",
doi = "10.1590/S1677-5538.IBJU.2014.04.07",
language = "English",
volume = "40",
pages = "493--498",
journal = "International Braz J Urol",
issn = "1677-5538",
publisher = "Brazilian Society of Urology",
number = "4",

}

Clinical utility of prostate-specific antigen mass ratio for prediction of prostate cancer detection on a repeated prostate biopsy. / Lee, Won Ki; Lee, Sang Chul; Hong, Sung Kyu; Lee, Sang Eun; Choi, Won Suk; Byun, Seok-Soo.

In: International Braz J Urol, Vol. 40, No. 4, 01.01.2014, p. 493-498.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical utility of prostate-specific antigen mass ratio for prediction of prostate cancer detection on a repeated prostate biopsy

AU - Lee, Won Ki

AU - Lee, Sang Chul

AU - Hong, Sung Kyu

AU - Lee, Sang Eun

AU - Choi, Won Suk

AU - Byun, Seok-Soo

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Purpose: To assess the clinical utility of the prostate-specific antigen mass ratio (PSA-MR), a newly developed PSA derivative, simply defined as the (i) PSA density (PSA-D) multiplied by the plasma volume or (ii) total PSA amount in circulation per prostate volume, for predicting prostate cancer (PCa) among men undergoing repeated prostate biopsy (PBx). Materials and Methods: Patients (n = 286), who underwent a repeated PBx, were analyzed. The various parameters associated with PCa detection were noted in each patient. PSA-MR was also calculated. Results: PCa was detected in 63 (22.0%) of 286 patients. PSA-MR was the independent predictor in the univariate- and multivariate logistic regression analyses (OR = 3.448, p = 0.001 and OR = 13.430, p = 0.033, respectively). A nomogram that incorporated PSA-MR was considered a useful tool (predictive accuracy: 79.2%, 95% CI: 0.726-0.858, p < 0.001). Furthermore, a nomogram that incorporated PSA-MR would have avoided 59.6% of unnecessary repeated PBx. The predictive accuracy of PSA-MR was also superior to that of PSA or PSA-D (p = 0.013 and 0.009, respectively). Conclusions: PSA-MR was an independent predictor, and its consideration would have avoided 59.6% of unnecessary repeated PBx for PCa detection. PSA-MR was also superior than PSA or PSA-D. Our results support the use of PSA-MR to facilitate counseling with patients after a negative initial PBx, and use of PSA-MR might reduce further unnecessary biopsies.

AB - Purpose: To assess the clinical utility of the prostate-specific antigen mass ratio (PSA-MR), a newly developed PSA derivative, simply defined as the (i) PSA density (PSA-D) multiplied by the plasma volume or (ii) total PSA amount in circulation per prostate volume, for predicting prostate cancer (PCa) among men undergoing repeated prostate biopsy (PBx). Materials and Methods: Patients (n = 286), who underwent a repeated PBx, were analyzed. The various parameters associated with PCa detection were noted in each patient. PSA-MR was also calculated. Results: PCa was detected in 63 (22.0%) of 286 patients. PSA-MR was the independent predictor in the univariate- and multivariate logistic regression analyses (OR = 3.448, p = 0.001 and OR = 13.430, p = 0.033, respectively). A nomogram that incorporated PSA-MR was considered a useful tool (predictive accuracy: 79.2%, 95% CI: 0.726-0.858, p < 0.001). Furthermore, a nomogram that incorporated PSA-MR would have avoided 59.6% of unnecessary repeated PBx. The predictive accuracy of PSA-MR was also superior to that of PSA or PSA-D (p = 0.013 and 0.009, respectively). Conclusions: PSA-MR was an independent predictor, and its consideration would have avoided 59.6% of unnecessary repeated PBx for PCa detection. PSA-MR was also superior than PSA or PSA-D. Our results support the use of PSA-MR to facilitate counseling with patients after a negative initial PBx, and use of PSA-MR might reduce further unnecessary biopsies.

KW - Biopsy

KW - Mass Screening

KW - Prostate-Specific Antigen

KW - Prostatic Neoplasms

UR - http://www.scopus.com/inward/record.url?scp=84910079938&partnerID=8YFLogxK

U2 - 10.1590/S1677-5538.IBJU.2014.04.07

DO - 10.1590/S1677-5538.IBJU.2014.04.07

M3 - Article

AN - SCOPUS:84910079938

VL - 40

SP - 493

EP - 498

JO - International Braz J Urol

JF - International Braz J Urol

SN - 1677-5538

IS - 4

ER -